Bristol-Myers Squibb Company (BMY)

$43.31 -2.67 (-5.81%)
Market Cap 95.36B
Revenue (ttm) 48.30B
Net Income (ttm) -8.95B
EPS (ttm) N/A
PE Ratio 6.38
Forward PE 7.40
Profit Margin -18.53%
Debt to Equity Ratio 2.85
Volume 44,531,300
Avg Vol 13,519,142
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 6%
Beta 0.36
Analysts Sell
Price Target $55.48

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 609 252 4621
Website: www.bms.com
Address:
Route 206 & Province Line Road, Princeton, United States
NoDinero
NoDinero Aug. 1 at 4:00 AM
$BMY ouch! I guess they need to shift to fat loss solutions rather than curing diseases to go up. You know, it's more important😉
0 · Reply
RedBull_ish
RedBull_ish Aug. 1 at 3:00 AM
$BMY on watch
0 · Reply
bignutz74
bignutz74 Aug. 1 at 2:40 AM
$BMY waiting for 40.00 a share to buy 1500 shares for 20 years from now. boring, up fairly safe.
0 · Reply
JRquiz
JRquiz Aug. 1 at 12:25 AM
$BMY Started a position here today. Missed the divi-ex date in July but will look forward to that next qtr.
0 · Reply
ndgt10
ndgt10 Jul. 31 at 10:51 PM
$BMY 37 test upcoming
1 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 10:07 PM
$BMY Q2 earnings beat expectations, but is the stock still a sell? 🤔 🔥 EPS of $1.46 vs. $1.07 estimate, but down from $2.07 a year ago 📈 Growth Portfolio revenues up 18%, driven by demand for Opdivo, Reblozyl, and Breyanzi, among others 📉 Legacy Portfolio dragged by generic impacts; 18.7% YTD share decline Opportunities and risks ahead 👉 https://www.zacks.com/stock/news/2644530/bristol-myers-beats-on-q2-earnings-and-sales-raises-25-sales-view?cid=sm-stocktwits-2-2644530-body-26&ADID=SYND_STOCKTWITS_TWEET_2_2644530_BODY_26
0 · Reply
FinDic
FinDic Jul. 31 at 10:05 PM
$BMY $BMY they beat and raised. I understand there are concerns about their legacy products competing against generics but at this PE 6.7 and a 5.7% dividend makes this an easy one. They already got ahead of DJT demand for lower prices, which is baked in. Today probably cleared out those that have been holding all the way down but down here this looks very attractive
0 · Reply
Risksomeguymanagement532
Risksomeguymanagement532 Jul. 31 at 8:03 PM
$BMY send it back in
0 · Reply
svk33
svk33 Jul. 31 at 7:50 PM
$BMY Oh shoot, this got caught in the crossfire as well. Wanna buy some and looks like 39's incoming as it broke the 46-48 neckline/balance range and that weekly hammer looks perfectly nasty. All healthcare is taking a beating RN but if you zoom on XLV over last decade or so, ATH's at 157, just a pullback, Barely 20% and we could easily get 10% more. Although kinda nuts with some valuations already. (7-8 Fwd PE lol) $NVO $MRK
0 · Reply
John89m
John89m Jul. 31 at 7:46 PM
$BMY this won’t fight back until we know what trump is doing, same with $LLY and $MRK
1 · Reply
Latest News on BMY
Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:40 PM EDT - 11 hours ago

Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

Jul 31, 2025, 3:35 PM EDT - 13 hours ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AMGN AZN GILD GSK JNJ LLY

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

Jul 31, 2025, 3:00 PM EDT - 13 hours ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AMGN AZN GILD GSK JNJ LLY

Trump pressures 17 pharma CEOs to cut US drug prices

Jul 31, 2025, 2:28 PM EDT - 14 hours ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AMGN AZN GILD GSK JNJ LLY

Trump posts letters to 17 pharmaceutical companies about drug prices

Jul 31, 2025, 2:19 PM EDT - 14 hours ago

Trump posts letters to 17 pharmaceutical companies about drug prices

ABBV GILD LLY PFE AMGN AZN GSK

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

Jul 31, 2025, 1:48 PM EDT - 14 hours ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

ABBV AMGN AZN GILD GSK JNJ LLY

Bristol Myers posts better-than-expected second quarter results on strength of top sellers

Jul 31, 2025, 7:01 AM EDT - 21 hours ago

Bristol Myers posts better-than-expected second quarter results on strength of top sellers

Bristol Myers Squibb Reports Second Quarter Financial Results for 2025

Jul 31, 2025, 6:59 AM EDT - 21 hours ago

Bristol Myers Squibb Reports Second Quarter Financial Results for 2025

Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' July DiviDogs

Jul 30, 2025, 5:59 PM EDT - 1 day ago

Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' July DiviDogs

BBY CAG EQR FRT KIM KMI MO

How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?

Jul 30, 2025, 10:15 AM EDT - 1 day ago

How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?

Bristol Myers, Bain Capital form new company to develop immunology drugs

Jul 28, 2025, 5:59 PM EDT - 3 days ago

Bristol Myers, Bain Capital form new company to develop immunology drugs

Bristol Myers Squibb and Bain Capital Form New Immunology Company

Jul 28, 2025, 5:05 PM EDT - 3 days ago

Bristol Myers Squibb and Bain Capital Form New Immunology Company

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Jul 28, 2025, 4:16 PM EDT - 3 days ago

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector

Jul 28, 2025, 2:06 PM EDT - 3 days ago

Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector

ABBV CI CVS HUM MRK XBI XLV

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

Jul 25, 2025, 6:59 AM EDT - 6 days ago

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

Jul 21, 2025, 6:59 AM EDT - 10 days ago

Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

July's 5 Dividend Growth Stocks With Yields Up To 7.96%

Jul 18, 2025, 2:46 PM EDT - 13 days ago

July's 5 Dividend Growth Stocks With Yields Up To 7.96%

ABBV APAM BLK EBF MRK NWE PFE

Bristol Myers' drug fails to meet main goal of late-stage anemia trial

Jul 18, 2025, 7:16 AM EDT - 13 days ago

Bristol Myers' drug fails to meet main goal of late-stage anemia trial

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Jul 18, 2025, 6:59 AM EDT - 13 days ago

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

Jul 17, 2025, 11:47 AM EDT - 14 days ago

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

PFE

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients

Jul 17, 2025, 7:21 AM EDT - 14 days ago

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients

PFE

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

Jul 17, 2025, 6:59 AM EDT - 14 days ago

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price

Jul 17, 2025, 6:30 AM EDT - 14 days ago

Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price

PFE

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Jul 14, 2025, 1:52 PM EDT - 17 days ago

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

Jul 11, 2025, 5:23 PM EDT - 20 days ago

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

AES AMCR ARE CAG CPB CVX D

Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends

Jul 10, 2025, 8:45 AM EDT - 21 days ago

Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends

BP ENB MO SLG TFC

Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company

Jul 10, 2025, 3:01 AM EDT - 22 days ago

Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company

June Readers Tagged 13 Ideal Dividend Dogs From 16 "Safer" Out Of 38 ReFa/Ro

Jul 8, 2025, 12:36 PM EDT - 23 days ago

June Readers Tagged 13 Ideal Dividend Dogs From 16 "Safer" Out Of 38 ReFa/Ro

ABR AGNC CAG CPB DOW DX ECC

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

Jul 8, 2025, 10:41 AM EDT - 23 days ago

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

GILD JNJ NVO PFE VRTX

2 Wonderful Dividends At Bargain Basement Prices

Jul 7, 2025, 11:45 AM EDT - 24 days ago

2 Wonderful Dividends At Bargain Basement Prices

REXR

Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset

Jul 1, 2025, 6:25 AM EDT - 4 weeks ago

Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset

Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)

Jun 29, 2025, 9:00 AM EDT - 4 weeks ago

Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

Jun 26, 2025, 10:05 PM EDT - 5 weeks ago

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

New vaccine panel meeting underway

Jun 26, 2025, 11:46 AM EDT - 5 weeks ago

New vaccine panel meeting underway

BDX MRK UNH ZBH

Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst

Jun 24, 2025, 11:58 AM EDT - 5 weeks ago

Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst

CI

10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June

Jun 24, 2025, 10:16 AM EDT - 5 weeks ago

10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June

BBY CAG EQR ETR FRT KEY KIM

I'm Buying Dividend Giants At Huge Discounts

Jun 20, 2025, 9:00 AM EDT - 5 weeks ago

I'm Buying Dividend Giants At Huge Discounts

ABBV CVX OXY PFE SHEL SLB TTE

Bristol Myers Squibb Announces Dividend

Jun 17, 2025, 4:16 PM EDT - 6 weeks ago

Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

Jun 16, 2025, 6:59 AM EDT - 6 weeks ago

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

Dividend Harvesting Portfolio Week 223: $22,300 Allocated, $2,310.77 In Projected Dividends

Jun 12, 2025, 9:00 AM EDT - 7 weeks ago

Dividend Harvesting Portfolio Week 223: $22,300 Allocated, $2,310.77 In Projected Dividends

ARE JEPI MO PDI QQQI VICI

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Jun 12, 2025, 6:59 AM EDT - 7 weeks ago

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

Jun 12, 2025, 6:45 AM EDT - 7 weeks ago

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Jun 11, 2025, 1:43 PM EDT - 7 weeks ago

Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Jun 11, 2025, 6:59 AM EDT - 7 weeks ago

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

Jun 10, 2025, 5:55 PM EDT - 7 weeks ago

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen

Jun 10, 2025, 12:47 PM EDT - 7 weeks ago

5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen

ACI CMCSA COP CVS CVX EPD ET

Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

Jun 6, 2025, 7:00 AM EDT - 7 weeks ago

Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

BNTX

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Jun 3, 2025, 3:34 PM EDT - 2 months ago

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

AZN GILD PFE AMGN BNTX MRK

Bristol Myers CEO explains why he's spending billions on BioNTech deal

Jun 2, 2025, 3:50 PM EDT - 2 months ago

Bristol Myers CEO explains why he's spending billions on BioNTech deal

BNTX

NoDinero
NoDinero Aug. 1 at 4:00 AM
$BMY ouch! I guess they need to shift to fat loss solutions rather than curing diseases to go up. You know, it's more important😉
0 · Reply
RedBull_ish
RedBull_ish Aug. 1 at 3:00 AM
$BMY on watch
0 · Reply
bignutz74
bignutz74 Aug. 1 at 2:40 AM
$BMY waiting for 40.00 a share to buy 1500 shares for 20 years from now. boring, up fairly safe.
0 · Reply
JRquiz
JRquiz Aug. 1 at 12:25 AM
$BMY Started a position here today. Missed the divi-ex date in July but will look forward to that next qtr.
0 · Reply
ndgt10
ndgt10 Jul. 31 at 10:51 PM
$BMY 37 test upcoming
1 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 10:07 PM
$BMY Q2 earnings beat expectations, but is the stock still a sell? 🤔 🔥 EPS of $1.46 vs. $1.07 estimate, but down from $2.07 a year ago 📈 Growth Portfolio revenues up 18%, driven by demand for Opdivo, Reblozyl, and Breyanzi, among others 📉 Legacy Portfolio dragged by generic impacts; 18.7% YTD share decline Opportunities and risks ahead 👉 https://www.zacks.com/stock/news/2644530/bristol-myers-beats-on-q2-earnings-and-sales-raises-25-sales-view?cid=sm-stocktwits-2-2644530-body-26&ADID=SYND_STOCKTWITS_TWEET_2_2644530_BODY_26
0 · Reply
FinDic
FinDic Jul. 31 at 10:05 PM
$BMY $BMY they beat and raised. I understand there are concerns about their legacy products competing against generics but at this PE 6.7 and a 5.7% dividend makes this an easy one. They already got ahead of DJT demand for lower prices, which is baked in. Today probably cleared out those that have been holding all the way down but down here this looks very attractive
0 · Reply
Risksomeguymanagement532
Risksomeguymanagement532 Jul. 31 at 8:03 PM
$BMY send it back in
0 · Reply
svk33
svk33 Jul. 31 at 7:50 PM
$BMY Oh shoot, this got caught in the crossfire as well. Wanna buy some and looks like 39's incoming as it broke the 46-48 neckline/balance range and that weekly hammer looks perfectly nasty. All healthcare is taking a beating RN but if you zoom on XLV over last decade or so, ATH's at 157, just a pullback, Barely 20% and we could easily get 10% more. Although kinda nuts with some valuations already. (7-8 Fwd PE lol) $NVO $MRK
0 · Reply
John89m
John89m Jul. 31 at 7:46 PM
$BMY this won’t fight back until we know what trump is doing, same with $LLY and $MRK
1 · Reply
Bogeymakr
Bogeymakr Jul. 31 at 7:43 PM
$BMY Slow bleed since 10am.. MM has this around the neck...Bought a little here. 43.45
0 · Reply
SJOldValueGuy
SJOldValueGuy Jul. 31 at 6:58 PM
$LNC Nailed this call. Cut half. …. Not so much on $BMY although straddle still printed.
0 · Reply
FinDic
FinDic Jul. 31 at 6:48 PM
$BMY Hoe we get some power hour love to help close this gap. Would be nice to have some strength going into tomorrow
0 · Reply
JClem_Stocks
JClem_Stocks Jul. 31 at 6:45 PM
$BMY beat earnings again, next quarter projected to be higher and expecting another beat. Trading at lows on the year. This will head to $60, easy adds
1 · Reply
dloeb
dloeb Jul. 31 at 5:35 PM
$GSK reward for beat and raise.... markets crazy and way undervalued with sweet dividend play for retirement accounts. Like the $BMY play as well - watching to position
0 · Reply
KennethCooke863
KennethCooke863 Jul. 31 at 4:58 PM
$BMY SEC filing dropped. Market: 😴
1 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Jul. 31 at 4:42 PM
$BMY adding more on push above that 44.10 area
0 · Reply
FinDic
FinDic Jul. 31 at 4:41 PM
$BMY we have a bounce and now need continuation to start the long road of recovery
0 · Reply
FinDic
FinDic Jul. 31 at 4:31 PM
$BMY would be nice if we could get a bounce here instead of this slow bleed
0 · Reply
Wallst45
Wallst45 Jul. 31 at 4:21 PM
$MDGL buyout hopes going up again after $BMY needs immediate
0 · Reply
Okadarlan
Okadarlan Jul. 31 at 4:04 PM
$BMY @Zonata
0 · Reply
MrNotSoNice
MrNotSoNice Jul. 31 at 4:03 PM
$BMY Too cheap. Sold puts here. 🧐📈💰💊
0 · Reply